ALNYLAM PHARMACEUTICALS, INC. (ALNY) vs Moderna, Inc. (MRNA)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | ALNY | MRNA |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $3.71B | $1.94B |
| Revenue growth (YoY) | ▲ 65.2% | ▼ 39.9% |
| Net income | $313.75M | -$2.82B |
| Gross margin | 81.8% | 55.3% |
| Diluted EPS | $2.33 | -$7.26 |
| Insider net (6 mo) | +15.8K sh • 2 sells • 0 buys | +429.0K sh • 12 sells • 0 buys |
| Institutional owners | 57 | 51 |
| Institutional value held | $30.04B | $21.77B |
| Next earnings (est.) | Around Feb 11, 2027 | Around Feb 12, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that develops therapeutics based on RNA interference (RNAi). Read more →
About Moderna, Inc. (MRNA)
Moderna is a pioneer in mRNA medicine. It uses its mRNA technology platform to develop vaccines and therapeutics for infectious disease, oncology, rare disease and other areas. Read more →
Source: SEC EDGAR.